Amgen’s $150 million investment aims to scale, diversify middle-market business
By Mark Alfred Special to the Business Times Thousand Oaks-based Amgen, one of the largest biotechnology companies in the world, invested $150 million into Project Black: an Ariel Investments fund intended to transform middle-market companies into certified minority-owned business enterprises. The fund, managed by Ariel’s private equity subsidiary Ariel Alternatives, is based in Chicago. It Read More →
Good Works: Women’s Fund of Santa Barbara hits million-dollar milestone
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Vital signs: California’s export sales leads the way, but are still below pre-pandemic times
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
The Trade Desk outperforms competition to close out fiscal year
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Street Smarts: Direct Relief commits 200K in aid to Turkey, Syria
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Portfolio watch
Mechanics Bank Wealth Management challenges the conventional wisdom of a slowing economy in its latest weekly update. And that wisdom also has held that the Fed would “pause their cycle of rate hikes” as early as this winter. But the December employment report shattered that view and now the extraordinary level of job creation “is Read More →
Atara’s cuts down net loss in 2022
Atara Biotherapeutics recorded a lower net loss in the fourth quarter and the entirety of fiscal year 2022, but missed expectations still led to an 8% decline in after-hours trading. Atara, a South San Francisco-based immunotherapy company with its major operations in Thousand Oaks, reported a net loss of $228.3 million, or 2.24 cents per Read More →
